Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There are only three therapies for IPF approved by the ...

IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

A brief course of morphine provided some relief for patients with cough related to idiopathic pulmonary fibrosis (IPF) in a small, phase II double-blind crossover trial. Two weeks of low-dose ...

The last time I spoke about United Therapeutics (UTHR) it was with respect to a Seeking Alpha article entitled "United Therapeutics: Ability To Expand Tyvaso To Large IPF Market". With respect to this ...